Raphael Simon

US Patent:

20110274714, Nov 10, 2011

Filed:

Jan 16, 2010

Appl. No.:

13/144336

Inventors:

Myron M. Levine - Columbia MD, US
Raphael Simon - Baltimore MD, US
James Galen - Syesvillek MD, US
Sharon Tennant - Baltimore MD, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 39/385
A61P 37/04
A61P 31/04
C12N 1/21

US Classification:

4241941, 42419711, 4352523

Abstract:

The present invention is drawn to attenuated serovar strains and , conjugate vaccines derived from these attenuated strains of and , comprising an O polysaccharide covalently linked to a flagellin protein, and methods for inducing an immune response in a subject comprising administering the attenuated strains and/or the conjugate vaccines of the invention.

US Patent:

20130129776, May 23, 2013

Filed:

Nov 6, 2012

Appl. No.:

13/670153

Inventors:

James E. Galen - Eldersburg MD, US
Sharon M. Tennant - Baltimore MD, US
Raphael Simon - Baltimore MD, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 39/385

US Classification:

42419711

Abstract:

The present invention is drawn to multivalent serovar conjugate vaccines comprising conjugates of A and optionally B, wherein the conjugates comprise a hapten antigen and a carrier antigen, wherein at least one of the hapten antigens or carrier antigens is characteristic of the serovar. The present invention also provides serovar reagent strains to produce the multivalent conjugate vaccines and attenuated serovars for use as vaccines.

US Patent:

20180194812, Jul 12, 2018

Filed:

Dec 14, 2017

Appl. No.:

15/842068

Inventors:

Raphael Simon - Baltimore MD, US
Alan Cross - Chevy Chase MD, US
Sharon Tennant - Baltimore MD, US

International Classification:

C07K 14/26
C07K 14/21
A61K 39/104
A61K 39/108
A61K 47/61
A61K 39/00

Abstract:

The present invention is drawn to conjugates and vaccine compositions comprising a flagellin or an antigenic fragment or derivative thereof linked to one or more surface polysaccharide antigens, such as O polysaccharide from serovars O1, O2O2O3, O4, O5, O7, O8 and O12. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

US Patent:

20180099038, Apr 12, 2018

Filed:

Apr 13, 2016

Appl. No.:

15/566333

Inventors:

- Baltimore MD, US
Raphael Simon - Baltimore MD, US
Myron M. Levine - Columbia MD, US

International Classification:

A61K 39/112
C12P 19/04
C08B 37/00

Abstract:

Longer chain antigenic O-polysaccharide chains for use as a hapten in conjugate vaccines can be produced in a controlled manner using recombinant Gram-negative bacteria that overexpress native or heterologous genes of the wzz family, for example wzzB. Bacteria expressing a chosen wzz gene have modified O-polysaccharide chain lengths, allowing the bacteria to produce lipopolysaccharides having the longer O-polysaccharides. The LPS produced by the bacteria can be hydrolyzed to form core-O-polysaccharide molecules that can be conjugated to a carrier molecule, for example flagellin, to produce a vaccine. The invention also provides recombinant bacteria producing the longer chain O-polysaccharides, the polysaccharide molecules, themselves, conjugated vaccines comprising the O-polysaccharides, pharmaceutical compositions and kits.

US Patent:

20170260240, Sep 14, 2017

Filed:

Sep 18, 2015

Appl. No.:

15/509041

Inventors:

Raphael Simon - Baltimore MD, US
Alan Cross - Chevy Chase MD, US
Sharon Tennant - Baltimore MD, US

International Classification:

C07K 14/26
A61K 39/104
A61K 39/108
C07K 14/21

Abstract:

The present invention is drawn to conjugates and vaccine compositions comprising a flagellin or an antigenic fragment or derivative thereof linked to one or more surface polysaccharide antigens, such as O5 polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.